BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

870 related articles for article (PubMed ID: 18544442)

  • 1. Targeting angiogenesis in head and neck cancer.
    Seiwert TY; Cohen EE
    Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
    Keedy VL; Sandler AB
    Cancer Sci; 2007 Dec; 98(12):1825-30. PubMed ID: 17892508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
    Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
    Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-angiogenic therapy against gastrointestinal tract cancers.
    Iwasaki J; Nihira S
    Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-angiogenic therapies in cancer: achievements and open questions.
    Ruegg C; Mutter N
    Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting angiogenesis for the treatment of sarcoma.
    Balasubramanian L; Evens AM
    Curr Opin Oncol; 2006 Jul; 18(4):354-9. PubMed ID: 16721130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination antiangiogenic therapy and radiation in head and neck cancers.
    Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
    Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes.
    Tysome JR; Lemoine NR; Wang Y
    Curr Opin Mol Ther; 2009 Dec; 11(6):664-9. PubMed ID: 20072943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor tyrosine kinase inhibitors as anti-angiogenic agents.
    Kim DW; Lu B; Hallahan DE
    Curr Opin Investig Drugs; 2004 Jun; 5(6):597-604. PubMed ID: 15242247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal effects of anti-angiogenesis therapy: update for the internist.
    Gurevich F; Perazella MA
    Am J Med; 2009 Apr; 122(4):322-8. PubMed ID: 19332223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
    Bran B; Bran G; Hörmann K; Riedel F
    Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparins and angiogenesis.
    Norrby K
    APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting angiogenesis with integrative cancer therapies.
    Yance DR; Sagar SM
    Integr Cancer Ther; 2006 Mar; 5(1):9-29. PubMed ID: 16484711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.